...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Bulletin du Cancer: Journal de l'Association Francaise pour l'Etude du Cancer >Pharmaco and diet based prostate cancer prevention [Pharmaco-prévention et nutri-prévention des cancers de la prostate]
【24h】

Pharmaco and diet based prostate cancer prevention [Pharmaco-prévention et nutri-prévention des cancers de la prostate]

机译：基于药物和饮食的前列腺癌预防[药物预防和营养预防前列腺癌]

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

In 2010, in France, 8,790 men died from prostate cancer despite a low and decreasing mortality rate. The individual risk/benefit ratio of prostate cancer screening is the focus of controversy and currently not in favor of a systematic screening program. Therefore, only prevention could reduce incidence, side effects of treatment and related mortality. Interestingly, prostate cancer prevention is also a field of controversy mainly about 5-alpha-reductase inhibitors. However, it could be expected that pharmaco-or diet-based prevention will be a huge tool for cancer control, even more for prostate cancer burden. This review comprehensively analyses which molecules or compounds could be used in preventive trials. With regard to pharmaco-prevention, three different kinds of drugs could be identified. First drugs, which aim at mainly or even solely reduce prostate cancer risk such as 5-alpha-reductase inhibitors and selective estrogen receptor modulators. Drugs, which aim at wider preventive impact such as: nonsteroidal anti-inflammatory drugs or difluoromethylornithine. Lastly, drugs for which reducing prostate cancer incidence is merely a side effect such as statins, metformin or histones desacetylase inhibitors. With regard to diet-based prevention, two main approaches could be identified: aliments and nutriments, on one hand, and vitamin and minerals, on the other. Interestingly if compounds reach experimental plausibility, natural foods or even global diet seem to have a higher impact. Lastly, besides assessment of efficacy, effectiveness required the critical step of compliance, which might actually be the weakest link of the prevention chain.
机译：2010年，在法国，尽管死亡率低且持续下降，仍有8790名男性死于前列腺癌。前列腺癌筛查的个体风险/获益比是争议的焦点，目前不支持系统的筛查程序。因此，只有预防才能降低发病率，治疗副作用和相关死亡率。有趣的是，前列腺癌的预防也是主要关于5-α-还原酶抑制剂的争议领域。但是，可以预期的是，基于药物或饮食的预防将是控制癌症的巨大工具，甚至对于前列腺癌的负担也将是更大的工具。这篇综述全面分析了哪些分子或化合物可用于预防性试验。关于药物预防，可以鉴定出三种不同的药物。最初主要针对或什至旨在降低前列腺癌风险的药物，例如5-α-还原酶抑制剂和选择性雌激素受体调节剂。针对更广泛的预防作用的药物，例如：非甾体类抗炎药或二氟甲基鸟氨酸。最后，降低前列腺癌发生率的药物仅仅是他汀类，二甲双胍或组蛋白脱乙酰基酶抑制剂等副作用。关于基于饮食的预防，可以确定两种主要方法：一方面是饮食和营养，另一方面是维生素和矿物质。有趣的是，如果化合物达到实验的合理性，那么天然食品甚至全球饮食似乎会产生更大的影响。最后，除了评估疗效外，有效性还需要遵守的关键步骤，这实际上可能是预防链中最薄弱的环节。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号